ArticleBreast cancer (Tokyo, Japan)2026
Reevaluating sentinel lymph node biopsy in older adults with T1 HR+/HER2- breast cancer: a SEER competing risk and nomogram study.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSentinel lymph node biopsy (SLNB) is the standard procedure for axillary staging. However, its necessity in older patients (≥ 70 years) with HR+/HER2- T1 breast cancer remains debated in the context of contemporary de-escalation strategies. Existing evidence often incompletely accounts for the competing risk of death in this population. We evaluated the association between SLNB and breast cancer-specific death (BCSD) using real-world data.
methodsWomen aged ≥ 70 years with HR+/HER2- T1 (≤ 20 mm) breast cancer treated with breast-conserving surgery between 2010 and 2021 were identified from the SEER database and classified into SLNB and No-SLNB groups. Propensity score matching (PSM) and Fine-Gray competing risk models were used to estimate subdistribution hazard ratios (sHRs) for BCSD and other-cause death (OCD). A prognostic nomogram was constructed.
resultsAmong 47,838 eligible patients, 37,732 underwent SLNB and 10,106 did not. After PSM, SLNB was associated with a lower 5-year cumulative incidence of BCSD (2.50% vs. 3.50%); differences in OCD were also observed. In multivariable competing risk analysis, SLNB remained independently associated with reduced BCSD (sHR 0.69, 95% CI 0.60-0.80). The association was most pronounced in patients aged ≥ 80 years and those with T1c (11-20 mm) tumors, whereas the absolute risk difference was minimal in the 1-5 mm subgroup. The nomogram showed good discrimination (time-dependent AUC up to 0.821 in the training set and 0.857 in the validation set) and calibration.
conclusionsIn this real-world cohort, SLNB was associated with lower BCSD in older adults with HR+/HER2- T1 breast cancer, particularly in those aged ≥ 80 years or with T1c tumors. While the incremental value of SLNB appears limited in ultra-low-risk groups, age alone should not dictate omission of axillary staging. The nomogram may support individualized decision-making.
Indexed as
Identifiers
42489813What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.